Cyclooxigenase-2 levels are increased in the lung tissue and bronchial tumors of patients with chronic obstructive pulmonary disease;La ciclooxigenasa-2 esta regulada al alza en el pulmon y en los tumoresbronquiales de pacientes con enfermedad pulmonar obstructiva cronica

Archivos de Bronconeumologia

Volumn 47, Issue 12, 2011, Pages 584-589

  Roca Ferrer, Jordi ^a,b   Pujols, Laura ^a,b   Agusti, Carlos ^a,b,c   Xaubet, Antoni ^a,b,c   Mullol, Joaquim ^a,b,c   Gimferrer, Josep M ^c,d   Picado, César ^a,b,c,d  

^a INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

^c HOSPITAL CLÍNIC   (Spain)

^d UNIVERSITY OF BARCELONA   (Spain)

Author keywords

Bronchial cancer; Chronic obstructive pulmonary disease (COPD); Cyclooxygenase

Indexed keywords

CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; MESSENGER RNA; PROSTAGLANDIN E2; RNA; TUMOR PROTEIN;

ARTICLE; BRONCHUS TUMOR; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; CYCLOOXYGENASE 1 GENE; CYCLOOXYGENASE 2 GENE; DISEASE ASSOCIATION; ENZYME ACTIVATION; ENZYME INDUCTION; GENE; GENE EXPRESSION REGULATION; HUMAN; HUMAN TISSUE; LUNG ADENOCARCINOMA; LUNG PARENCHYMA; MALE; PNEUMOTHORAX; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SQUAMOUS CELL CARCINOMA; TISSUE LEVEL; WESTERN BLOTTING; ADENOCARCINOMA; AGED; CANCER INVASION; COCARCINOGENESIS; COMPARATIVE STUDY; ENZYMOLOGY; GENETICS; LUNG; METABOLISM; MIDDLE AGED; SMOKING; ADULT; BRONCHUS CANCER; BRONCHUS MUCOSA; CANCER PATIENT; LUNG CANCER;

ADENOCARCINOMA; AGED; BRONCHIAL NEOPLASMS; CARCINOMA, SQUAMOUS CELL; COCARCINOGENESIS; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; DINOPROSTONE; ENZYME INDUCTION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LUNG; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM PROTEINS; PNEUMOTHORAX; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RNA, MESSENGER; RNA, NEOPLASM; SMOKING;

EID: 85047699194     PISSN: 03002896     EISSN: 15792129     Source Type: Journal    
DOI: 10.1016/j.arbr.2011.05.004     Document Type: Article

References (28)

1. Ballaz S., Mulshine J.L. The potential contributions of chronic inflammation to lung carcinogenesis. Clin Lung Cancer 2003, 5:46-62.
2. Tockman M.S., Anthonisen N.R., Wright E.C., Donithan M.G. Airway obstruction and the risk for lung cancer. Ann Intern Med 1987, 106:512-518.
3. Turner M.C., Chen Y., Krewski D., Calle E.E., Thum M.J. Chronic obstructive pulmonary disease is associated with lung cancer mortality in a prospective study of never smokers. Am J Respir Crit Care Med 2007, 176:285-290.
4. Young R.P., Hopkins R.J., Christmas T., Black P.N., Metcalf P., Gamble G.D. COPD prevalence is increased in lung cancer independent of age, gender, and smoking history. Eur Respir J 2009, 34:380-386.
5. Funk C.D. Prostaglandin and leukotrienes: advances in eicosanoid biology. Science 2001, 294:1871-1875.
6. Wang M.T., Honn K.V., Nie D. Cyclooxygenases, prostanoids, and tumor progression. Cancer Metast Rev 2007, 26:525-534.
7. Greenhough A., Smart H.J., Moore A.E., Roberts H.R., Williams A.C., Paraskeva C., et al. The COX-2/PGE2 pathway: key roles in the hallmarks of cancer and adaptation to the tumour microenvironment. Carcinogenesis 2009, 30:377-386.
8. Xaubet A., Roca-Ferrer J., Pujols L., Ramírez J., Mullol J., Marin-Arguedas A., et al. Cyclooxygenase-2 is up-regulated in lung parenchyma of chronic obstructive pulmonary disease and down-regulated in idiopathic pulmonary fibrosis. Sarcoidosis Vasc Diffuse Lung Dis 2004, 21:35-42.
9. Togo S., Holz O., Liu X., Sugiura H., Kamio K., Wang X., et al. Lung fibroblast repair functions in patients with chronic obstructive pulmonary disease are altered by multiple mechanisms. Am J Respir Crit Care Med 2008, 178:248-260.
10. Martey C.A., Pollock S.J., Turner ChK, O'Reilly K.M.A., Baglole C.J., Phipps R.P., et al. Cigarette smoke induces cyclooxygenase-2 and microsomal prostaglandin E2 synthase in human lung fibroblasts: implications for lung inflammation and cancer. Am J Physiol Cell Mol Physiol 2004, 287:L9981.
11. Profita M., Sala A., Bonanno A., Ricobono L., Ferraro M., La Grutta S., et al. Chronic obstructive pulmonary disease and neutrophil infiltration: role of cigarette smoke and cyclooxygenase products. Am J Physiol Lung Cell Mol Physiol 2010, 298:L2261.
12. a ed.
13. Diagnóstico y estadificación del carcinoma broncogénico. Arch Bronconeumol 2001, 37:495-503. Grupo cooperativo de carcinoma broncogénico de la Sociedad Española de Neumología y Cirugía Torácica.
14. Peces-Barba G., Barberà J.A., Agustí A., Casanova C., Casas A., Izquierdo J.L., et al. Guía clínica SEPAR-ALAT de diagnóstico y tratamiento de la EPOC. Arch Bronconeumol 2008, 44:271-281.
15. Picado C., Fernandez-Morata J.C., Juan M., Roca-Ferrer J., Fuentes M., Xaubet A., et al. J. Cyclooxygenase-2 mRNA is down-expressed in nasal polyps from aspirin-sensitive asthmatics. Am J Respir Crit Care Med 1999, 160:291-296.
16. Yoshimoto A., Kasahara K., Kawashima A., Fujimura M., Nakao S. Characterization of the prostaglandine biosynthetic pathway in non-small cell lung cancer: A comparison with small cell lung cancer and correlation with angiogenesis, angiogenic factors and metastases. Oncol Rep 2005, 13:1049-1057.
17. Yuan A., Yu C.Y., Shun C.T., Luh K.T., Kuo K.T., Kuo S.H., et al. Total cyclooxygenase-2 mRNA levels correlates with vascular endothelial growth factor mRNA levels, tumor angiogenesis and prognosis in non-small cell lung cancer patients. Int J Cancer 2005, 115:545-555.
18. Roca-Ferrer J., Pujols L., Garner S., Moreno A., Pumarola F., Mullol J., et al. Upregulation of COX-1 and COX-2 in nasal polyps in cystic fibrosis. Thorax 2006, 61:592-596.
19. Wallace J.L., McNight W., Reuter B.K. NSAID-induced gastric damage in rats: requirement for inhibition of both cyclooxygenases 1 and 2. Gastroenterology 2000, 119:706-714.
20. Huang R.Y., Chen G.G. Cigarette smoking, cyclooxygenase-2 pathway and cancer. Biochimica et Biophysica Acta 2011, 1815:158-169.
21. Rothwell P.M., Fowkes G.R., Belch J.F., Warlow C., Meade T. Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised studies. Lancet 2011, 377:31-41.
22. Harris R.E., Beebe-Donk J., Alshafie G.A. Reduced risk of human lung cancer by selective cyclooxygenase 2 (COX-2) blockade: Results of a case control disease. Int J Biol Sci 2007, 3:328-334.
23. Wolff H., Saukkonen K., Anttila S., Karjalainen A., Vainio H., Ristimäki A. Expression of cyclooxygenase-2 in human lung carcinoma. Cancer Res 1998, 58:4997-5001.
24. Laga A.C., Zander D.S., Cagle P.T. Prognostic significance of cyclooxygenase 2 expression in 259 cases of non-small lung cancer. Arch Pathol Lab Med 2005, 129:1113-1117.
25. Okada F., KaAng Y., Chong-Jen Y., Chia-Tung S., Kwen-Tay L., Sow-Hsong K., et al. Total cyclooxygenase-2 mRNA levels correlate with vascular endothelial growth factor mRNA levels, tumor angiogenesis and prognosis in non-small cell lung cancer patients. Int J Cancer 2005, 115:545-555.
26. Zhongxing L., Komaki R., Milas L., Yuan C., Kies M., Chang J.Y., et al. A phase I clinical trial of thoracic radiotherapy and concurrent celecoxib for patients with unfavourable performance status unoperable/unresectable non-small cell lung cancer. Clin Cancer Res 2005, 11:3342-3348.
27. Fontaine E., McShane J., Page R., Shackcloth M., Mediratta N., Carr M., et al. Aspirin and non-small cell lung cancer resections: effect on long-term survival. Eur J Cardio-Thoracic Surgery 2010, 38:21-26.
28. Mascaux C., Martin B., Verdebout J.M., Ninane V., Sculler J.P. COX-2 expression during early lung squamous cell carcinoma oncogenesis. Eur Respir J 2005, 26:198-203.